Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.00 Analyst target: $5.50 Upside: 450.00%
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
See the full interactive analysis & chart →Informational only — not investment advice.